AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25124303
Drug: Cocaine self-administration
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine self-administration
Trial: 20707210
Drug: Songling Xuemaikang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets
Trial: 20707210
Drug: Shuxuetong +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuetong + Aspirin enterie coated tablets
Trial: 11835076
Drug: HCTZ plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ plus perindopril 2 mg
Trial: 11835076
Drug: HCTZ plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ plus perindopril 4 mg
Trial: 11835076
Drug: HCTZ plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ plus perindopril 8 mg
Trial: 3284266
Drug: Peroral opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral opioid therapy (SO)
Trial: 3284266
Drug: Epidural catheter
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural catheter connected to an implanted injection port (Port)
Trial: 30079329
Drug: L‐ornithine L‐aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐ornithine L‐aspartate
Trial: 27386641
Drug: Telbivudine Tablet
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telbivudine Tablet (600 mg, once per day) combined with Jianpi Bushen Recipe (twice per day)
Trial: 27386641
Drug: Telbivudine Tablet
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telbivudine Tablet alone
Trial: 24607797
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg misoprostol vaginally 6 hours before HSG
Trial: 24607797
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac potassium orally 45 to 60 minutes before HSG
Trial: 20394870
Drug: Omega-3 ethyl
RxNorm normalized name: Cyanocobalamin/Omega-3 Fatty Acids/Pyridoxine 6 MCG-725 MG-8 MG Oral Capsule, Liquid Filled [VITAMIN B PLUS+ OMEGA-3 ETHYL ESTER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 ethyl esters (1 g/day)
Trial: 389827
Drug: Bacampicillin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin (800 mg t.i.d. for 10 days)
Trial: 389827
Drug: Pivampicillin (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (700 mg t.i.d. for 10 days)
Trial: 28945060
Drug: Micronized purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized purified flavonoid fraction (MPFF) 1000 mg daily for 2 weeks before and for at least 2 months after sclerotherapy
Trial: 24305085
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with immediate feedback for each session
Trial: 24305085
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without feedback
Trial: 18199015
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery therapy (listening to a 25-minute guided imagery CD twice a day for 8 weeks)
Trial: 18199015
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (resting for 25 minutes twice daily for 8 weeks)
Trial: 10440419
Drug: Clopidogrel 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 50 mg
Trial: 10440419
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg (multiple doses for 14 days)
Trial: 10440419
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg (long-term study for 12 weeks)
Trial: 27010625
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab administered monthly
Trial: 27010625
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab administered as needed (PRN)
Trial: 27010625
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab administered monthly
Trial: 27010625
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab administered as needed (PRN)
Trial: 27010625
Drug: PRN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN treatment
Trial: 25439809
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (67 μg/kg/day) for 1 year followed by 2 years of randomized GH treatment (67 μg/kg/day, 35 μg/kg/day, or IGF‐I titrated)
Trial: 18284652
Drug: Lactulose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (10 g b.d.)
Trial: 11230031
Drug: Cognitive-analytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-analytic therapy (CAT) for 7 months
Trial: 11230031
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy for 1 year
Trial: 11230031
Drug: Low contact,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low contact, 'routine' treatment for 1 year
Trial: 3427224
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus Adriamycin followed by high-dose methotrexate plus cisplatin
Trial: 3427224
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate plus cisplatin followed by Cyclophosphamide plus Adriamycin
Trial: 21597989
Drug: Methylphenidate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (all doses)
Trial: 18334815
Drug: Beta-glucan-enriched ready
RxNorm normalized name: yeast, beta-D-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-glucan-enriched ready meal (4 g of oat beta-glucans)
Trial: 9322828
Drug: Valsartan 80/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80/160 mg
Trial: 9322828
Drug: Valsartan 80/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80/80 mg twice daily
Trial: 9322828
Drug: Lisinopril 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10/20 mg
Trial: 9322828
Drug: Valsartan and
RxNorm normalized name: valsartan and aliskiren
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan and Lisinopril
Trial: 7690462
Drug: L-697,661 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-697,661 (25 mg twice a day)
Trial: 7690462
Drug: L-697,661 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-697,661 (100 mg three times a day)
Trial: 7690462
Drug: L-697,661 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-697,661 (500 mg twice a day)
Trial: 7690462
Drug: Zidovudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (100 mg five times a day)
Trial: 7690462
Drug: L-697,661 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-697,661 (all doses)
Trial: 7690462
Drug: L-697,661 (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-697,661 (higher doses)
Trial: 29958570
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200 mg via two infusions)
Trial: 29958570
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron polymaltose complex (100 mg orally twice a day for 8 weeks)
Trial: 26763349
Drug: Lenalidomide starting
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide starting dose of 5 mg/d
Trial: 26763349
Drug: Lenalidomide starting
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide starting dose of 10 mg/d
Trial: 26763349
Drug: Lenalidomide starting
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide starting dose of 15 mg/d
Trial: 26763349
Drug: Escalated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated treatment (to 15 or 20 mg/d)
Trial: 26763349
Drug: Lenalidomide (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (any starting dose)
Trial: 24531938
Drug: Periarticular infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular infiltration analgesia (PIA) with 60 ml 0.5 % ropivacaine and 0.3 mg epinephrine
Trial: 24531938
Drug: Sciatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sciatic nerve block (SNB) with 20 ml 0.375 % ropivacaine and periarticular infiltration with 20 ml normal saline and 0.3 mg epinephrine
Trial: 22218122
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (500 mg, 2 tablets per day for 5 days before transplantation)
Trial: 21535171
Drug: Narrow band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow band ultraviolet B (NBUVB) + isotretinoin (0.5 mg/kg/day)
Trial: 24645
Drug: Halazepam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halazepam (40 mg starting dose, adjusted every 2 hours, total daily dose not exceeding 600 mg)
Trial: 24528686
Drug: Armolipid Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armolipid Plus (nutraceutical combination containing red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid)
Trial: 17621463
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV)
Trial: 15304466
Drug: Bivalirudin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for the duration of PCI) with provisional Gp IIb/IIIa inhibition
Trial: 15304466
Drug: Heparin (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (65 U/kg bolus) with planned Gp IIb/IIIa inhibition
Trial: 30853361
Drug: Dose-dense taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense taxane chemotherapy (ddTC)
Trial: 30853361
Drug: Conventional taxane
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional taxane and carboplatin chemotherapy (TC)
Trial: 22584132
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (n = 162)
Trial: 22584132
Drug: Continuation without
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation without insulin detemir (n = 157)
Trial: 19084016
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a (180 mug) weekly for 48 weeks and ribavirin (1000-1200 mg) daily for HCV genotype 1
Trial: 19084016
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily for HCV genotypes 2 or 3
Trial: 16915367
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg after pretreatment with clarithromycin 800 mg/day
Trial: 16915367
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg after pretreatment with fluvoxamine 50 mg/day
Trial: 15736352
Drug: Cyclizine 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclizine 0.7 mg/kg during surgery followed by PCA with cyclizine 2 mg per demand
Trial: 15736352
Drug: Droperidol 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.04 mg/kg during surgery followed by PCA with droperidol 0.05 mg per demand
Trial: 10598606
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg rapacuronium
Trial: 10598606
Drug: Mivacurium (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.25 mg/kg)
Trial: 10598606
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (1.5 mg/kg rapacuronium, 2.5 mg/kg rapacuronium, succinylcholine, mivacurium)
Trial: 1927129
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with Cisplatin and 5‐Fluorouracil over 6 cycles
Trial: 1927129
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with Cisplatin and 5‐Fluorouracil over 3 cycles plus Telecobalt‐irradiation to 50 Gy
Trial: 25539762
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 mg daily for 7 days)
Trial: 24066672
Drug: 80 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg Beraprost Sodium (BPS) daily for 12 weeks
Trial: 21852698
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care at time of pregnancy confirmation with sequential partner testing (n = 158)
Trial: 21852698
Drug: Secondary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary care by midwives with sequential partner testing (standard care, n = 115)
Trial: 9507926
Drug: Incorrect irregular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incorrect irregular participle forms (e.g., *prendato instead of preso)
Trial: 9507926
Drug: Incorrect regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incorrect regular participle forms (e.g., *parlito, *dormato)
Trial: 7530028
Drug: Methoxamine 10
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine 10 mg i.m. 15 min before spinal anaesthesia
Trial: 3123118
Drug: gamma-L-glutamyl-L-dopa (gludopa)
RxNorm normalized name: gamma-L-Glutamyl-L-cysteinyl-glycine
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-L-glutamyl-L-dopa (gludopa) at a dose of 25 micrograms min-1 kg-1
Trial: 3123118
Drug: gamma-L-glutamyl-L-tyrosine (glutyrosine)
RxNorm normalized name: gamma-L-Glutamyl-L-cysteinyl-glycine
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-L-glutamyl-L-tyrosine (glutyrosine) at a dose of 25 micrograms min-1 kg-1
Trial: 30917121
Drug: Combination-prevention-package (behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination-prevention-package (behaviour change communication, condom promotion, HIV testing, voluntary male medical circumcision, referral for anti-retroviral therapy if HIV-positive)
Trial: 30917121
Drug: Combination-prevention-package
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination-prevention-package
Trial: 29141719
Drug: Chloroquine plus
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine plus primaquine (0.25 mg base/kg/day for 14 days)
Trial: 14707788
Drug: GW433908 (908),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW433908 (908), 1400 mg BID
Trial: 14707788
Drug: Nelfinavir (NFV),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir (NFV), 1250 mg BID
Trial: 7942719
Drug: Endoscopic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapy (injection or heater probe therapy)
Trial: 2681281
Drug: Sulconazole nitrate
RxNorm normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulconazole nitrate 1% cream applied twice daily
Trial: 1090014
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional drugs (Control Group I)
Trial: 29309700
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (800 mcg)
Trial: 29309700
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine (300 mcg)
Trial: 23553992
Drug: 400 or
RxNorm normalized name: Nico-400 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 or 2000 IU vitamin D3 daily for 6 months
Trial: 21292711
Drug: Training in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training in a modified version of the neonatal resuscitation protocol and single dose amoxicillin coupled with facilitated referral of infants to a health centre
Trial: 19691854
Drug: Clonidine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (initial loading dose of 0.15 mg followed by an infusion of 0.5 mg over 24 hours; increased to 0.3 mg, 0.45 mg, and 0.6 mg at subsequent levels)
Trial: 16478814
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration using a patch that delivers 300 microg daily
Trial: 15577594
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ANN and clinical interpretation
Trial: 11041065
Drug: Single cytospin
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cytospin slide preparation
Trial: 9001831
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg QID
Trial: 6384453
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) administered twice daily
Trial: 6384453
Drug: Cefaclor administered
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor administered twice daily
Trial: 28368521
Drug: Bolus AVP
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus AVP after CRH infusion
Trial: 21422032
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone treatment (PC)
Trial: 17533063
Drug: HRT discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT discontinuation
Trial: 15345498
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg injections, twice weekly for 12 weeks)
Trial: 11141221
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g intravenous ampicillin and sulbactam (AS) before incision
Trial: 2914116
Drug: ioxaglate 280
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioxaglate 280 mg I/ml
Trial: 2914116
Drug: metrizoate 280
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metrizoate 280 mg I/ml
Trial: 2914116
Drug: metrizoate 370
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metrizoate 370 mg I/ml
Trial: 4262210
Drug: Carisoprodol 350
RxNorm normalized name: carisoprodol 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisoprodol 350 mg, four times daily for four days
Trial: 4262210
Drug: Butabarbital 15
RxNorm normalized name: butabarbital 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butabarbital 15 mg, four times daily for four days
Trial: 4262210
Drug: Placebo, four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, four times daily for four days
Trial: 31156218
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation including mechanotherapy and cognitive stimulation using tablet technologies
Trial: 28005440
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol (300,000 IU)
Trial: 28005440
Drug: Low-dose cholecalciferol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cholecalciferol (75,000 IU)
Trial: 16963037
Drug: Single-dose GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose GnRH antagonist
Trial: 16963037
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol for GnRH agonist